{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=3", "query": { "intervention": "capecitabine", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 760, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T00:24:15.475Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07007559", "title": "ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer, Metastatic" ], "interventions": [ { "name": "Evorpacept (ALX148)", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ALX Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-12-10", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07007559" }, { "nct_id": "NCT00827580", "title": "Eniluracil Hand Foot Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colon Cancer" ], "interventions": [ { "name": "Eniluracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2009-01", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2018-05-30", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00827580" }, { "nct_id": "NCT01267240", "title": "Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage IVA Hypopharyngeal Squamous Cell Carcinoma", "Stage IVA Laryngeal Squamous Cell Carcinoma", "Stage IVA Oral Cavity Squamous Cell Carcinoma", "Stage IVA Oropharyngeal Squamous Cell Carcinoma", "Stage IVB Hypopharyngeal Squamous Cell Carcinoma", "Stage IVB Laryngeal Squamous Cell Carcinoma", "Stage IVB Oral Cavity Squamous Cell Carcinoma", "Stage IVB Oropharyngeal Squamous Cell Carcinoma", "Stage IVC Hypopharyngeal Squamous Cell Carcinoma", "Stage IVC Laryngeal Squamous Cell Carcinoma", "Stage IVC Oral Cavity Squamous Cell Carcinoma", "Stage IVC Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 25, "start_date": "2010-12", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-04-14", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 9, "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Martinez", "state": "California" }, { "city": "Martinez", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01267240" }, { "nct_id": "NCT02394535", "title": "Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v6 and v7", "Stage IIA Pancreatic Cancer AJCC v6 and v7", "Stage IIB Pancreatic Cancer AJCC v6 and v7", "Stage III Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 25, "start_date": "2015-11-12", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2022-09-02", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 5, "location_summary": "Houston, Texas • League City, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02394535" }, { "nct_id": "NCT06797635", "title": "Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Epirubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 372, "start_date": "2025-03-20", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 8, "location_summary": "Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Billings", "state": "Montana" }, { "city": "Tigard", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06797635" }, { "nct_id": "NCT00996333", "title": "Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine, Docetaxel, Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 46, "start_date": "2003-06", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-07-25", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00996333" }, { "nct_id": "NCT00159432", "title": "Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2005-02", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-07-29", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00159432" }, { "nct_id": "NCT00193609", "title": "Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Unknown Primary" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2004-09", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2013-11-11", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 10, "location_summary": "Jacksonville, Florida • Terre Haute, Indiana • Bowling Green, Kentucky + 7 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Terre Haute", "state": "Indiana" }, { "city": "Bowling Green", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00193609" }, { "nct_id": "NCT07335497", "title": "CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced / Metastatic Solid Tumors" ], "interventions": [ { "name": "CR-001", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "trifluridine and tipiracil", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Gemcitabin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crescent Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2026-02-17", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07335497" }, { "nct_id": "NCT02079220", "title": "A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Arm A", "type": "DRUG" }, { "name": "Arm B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James J Lee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-03", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2017-07-31", "last_synced_at": "2026-10-24T00:24:15.475Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02079220" } ] }